旧问题的新概念:子宫内膜增生的诊断
本文综述子宫内膜增生(EH)的分类系统、免疫组化标志物及基因组分析在风险分层中的证据,检索2000年1月至2016年1月文献;提出多标志物组合策略可能提供更多信息,因目前无单一标志物能承担全部角色。
要点
- 子宫内膜增生以腺体与间质比例增加为特征,非典型形式被视为癌前病变。
- 子宫内膜上皮内瘤变(EIN)概念反映突变激活的单克隆癌前病变,与旧观点根本不同。
- 多种免疫组化标志物候选用于EH诊断和进展风险标记,但无单一标志物能承担全部角色。
核心结论
- 提出多标志物组合策略可能提供更多信息,因目前无单一标志物能承担全部角色。
- 深入理解EC癌前阶段将有助于早期诊断和风险分层。
研究设计与样本
- 检索PubMed、Medline和Cochrane数据库2000年1月至2016年1月的同行评议原始研究和综述。
- 检索词包括子宫内膜增生、子宫内膜上皮内瘤变、非典型增生、复杂非典型增生、生物标志物、免疫组化、进展、基因组、分类和分层。
主要发现
- 子宫内膜增生以腺体与间质比例较正常增殖期内膜增加为特征。
- 非典型EH被视为癌前病变,与进展为子宫内膜样癌的风险相关。
- 传统组织病理学分类系统的诊断可重复性差异大,标准化管理具挑战性。
- EC是发达国家最常见妇科恶性肿瘤,发病率上升,40-44岁年龄组增幅令人担忧。
- EIN概念为突变激活的单克隆癌前病变,代表对旧有非拮抗雌激素刺激导致增生并累积细胞异型性直至癌变观点的根本转变。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Endometrial hyperplasia (EH) is a uterine pathology representing a spectrum of morphological endometrial alterations. It is predominantly characterized by an increase in the endometrial gland-to-stroma ratio when compared to normal proliferative endometrium. The clinical significance of EH lies in the associated risk of progression to endometrioid endometrial cancer (EC) and 'atypical' forms of EH are regarded as premalignant lesions. Traditional histopathological classification systems for EH exhibit wide and varying degrees of diagnostic reproducibility and, as a consequence, standardized patient management can be challenging. OBJECTIVE AND RATIONALE: EC is the most common gynaecological malignancy in developed countries. The incidence of EC is rising, with alarming increases described in the 40-44-year-old age group. This review appraises the current EH classification systems used to stratify women at risk of malignant progression to EC. In addition, we summarize the evidence base regarding the use of immunohistochemical biomarkers for EH and discuss an emerging role for genomic analysis. SEARCH METHODS: PubMed, Medline and the Cochrane Database were searched for original peer-reviewed primary and review articles, from January 2000 to January 2016. The following search terms were used: 'endometrial hyperplasia', 'endometrial intraepithelial neoplasia', 'atypical hyperplasia', 'complex atypical hyperplasia', 'biomarker', 'immunohistochemistry', 'progression', 'genomic', 'classification' and 'stratification'. OUTCOMES: Recent changes to EH classification reflect our current understanding of the genesis of endometrioid ECs. The concept of endometrial intraepithelial neoplasia (EIN) as a mutationally activated, monoclonal pre-malignancy represents a fundamental shift from the previously held notion that unopposed oestrogenic stimulation causes ever-increasing hyperplastic proliferation, with accumulating cytological atypia that imperceptibly leads to the development of endometrioid EC. Our review highlights several key biomarker candidates that have been described as both diagnostic tools for EH and markers of progression to EC. We propose that, moving forwards, a 'panel' approach of combinations of the immunohistochemical biomarkers described in this review may be more informative since no single candidate can currently fill the entire role. WIDER IMPLICATIONS: EC has historically been considered a predominantly postmenopausal disease. Owing in part to the current unprecedented rates of obesity, we are starting to see signs of a shift towards a rising incidence of EC amongst pre- and peri-menopausal woman. This creates unique challenges both diagnostically and therapeutically. Furthering our understanding of the premalignant stages of EC development will allow us to pursue earlier diagnosis and facilitate appropriate stratification of women at risk of developing EC, permitting timely and appropriate therapeutic interventions.
引用
- Sanderson PA, Critchley HO, Williams AR, et al. New concepts for an old problem: the diagnosis of endometrial hyperplasia. Hum Reprod Update. 2017. PMID: 27920066. doi:10.1093/humupd/dmw042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。